TELA Bio (NASDAQ:TELA) Earns Buy Rating from Analysts at Canaccord Genuity

Canaccord Genuity initiated coverage on shares of TELA Bio (NASDAQ:TELA) in a research report sent to investors on Tuesday, Benzinga reports. The firm issued a buy rating and a $19.00 target price on the stock.

Separately, Piper Jaffray Companies assumed coverage on TELA Bio in a report on Tuesday. They issued an overweight rating and a $17.00 price target on the stock.

TELA Bio stock opened at $12.96 on Tuesday. TELA Bio has a 1 year low of $10.78 and a 1 year high of $15.05.

In other news, Director Matt Zuga acquired 86,121 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were purchased at an average cost of $12.09 per share, for a total transaction of $1,041,202.89. Also, major shareholder Orbimed Advisors Llc bought 384,615 shares of TELA Bio stock in a transaction on Friday, November 8th. The shares were purchased at an average cost of $12.09 per share, with a total value of $4,649,995.35.

About TELA Bio

TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

See Also: Put Option Volume

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.